OPT101

Op-T LLC · Phase 2 active Small molecule

At a glance

Generic name	OPT101
Also known as	15-mer peptide
Sponsor	Op-T LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus (PHASE2)
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis (PHASE1)
1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide. (PHASE1)
OPT101 in Type 1 Diabetes Patients (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OPT101 CI brief — competitive landscape report
OPT101 updates RSS · CI watch RSS
Op-T LLC portfolio CI